Development And Validation of RP-HPLC Method for Semaglutide in Bulk and Pharmaceutical Dosage Form
International Journal of Scientific Research in Science and Technology · 22.08.2026 · 13 (4) · 480-487
DOI: 10.32628/ijsrst2613466 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Scientific Research in Science and Technology, online erschienen am 22.08.2026. Verfasst von Suyash Shashikant Ingle und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an important therapeutic agent used in the management of type 2 diabetes mellitus and obesity, necessitating reliable and robust analytical methods for quality control of its pharmaceutical formulations. The present study aimed to develop and optimize a simple, accurate, precise, rapid, and specific reverse-phase high-performance liquid chromatography (RP-HPLC) method for the estimation of semaglutide using a Quality by Design (QbD) approach. Chromatographic separation was achieved on an Agilent Zorbax SB-Aq column (250 × 4.6 mm, 5 µm) using acetonitrile and buffer in a ratio of 50:50% v/v as the mobile phase at a flow rate of 1.0 mL/min, with acetonitrile (50:50% v/v) as the diluent. The analyte was detected by UV at 240 nm, with a column temperature of 30°C, injection volume of 10 µL, and total run time of 10 min. Semaglutide exhibited a retention time of 3.22 min. The method demonstrated linearity over the concentration range of 30–70 µg/mL and showed satisfactory specificity, accuracy, precision, sensitivity, and peak characteristics. Method validation was performed in accordance with International Council for Harmonization (ICH) guidelines, and the validation results confirmed the reliability, reproducibility, and statistical validity of the developed method. Robustness studies further demonstrated that minor deliberate variations in chromatographic conditions did not significantly influence method performance. Overall, the integration of QbD principles enhanced method understanding and control, resulting in a robust, reliable, and regulatory-compliant RP-HPLC method suitable for routine quality control and quantitative analysis of semaglutide in bulk drug and pharmaceutical dosage forms.
Zitieren
APA
Ingle, S. S., Patil, P. R., Patil, L. K., Hajgude, P. B., Mirza, A. A., Yemul, P. K., & Harihar, N. B. (2026). Development And Validation of RP-HPLC Method for Semaglutide in Bulk and Pharmaceutical Dosage Form. International Journal of Scientific Research in Science and Technology, 13(4), 480-487. https://doi.org/10.32628/ijsrst2613466
Vancouver
Ingle SS, Patil PR, Patil LK, Hajgude PB, Mirza AA, Yemul PK, et al. Development And Validation of RP-HPLC Method for Semaglutide in Bulk and Pharmaceutical Dosage Form. International Journal of Scientific Research in Science and Technology. 2026;13(4):480-487. doi:10.32628/ijsrst2613466
BibTeX
@article{Ingle2026,
author = {Ingle, Suyash Shashikant and Patil, Priyanka Rajkheshar and Patil, Laxmi Kashinath and Hajgude, Pratiksha Bharat and Mirza, Alfiya Ahmad and Yemul, Pooja Keshav and Harihar, Nikita Bhimrao},
title = {Development And Validation of RP-HPLC Method for Semaglutide in Bulk and Pharmaceutical Dosage Form},
journal = {International Journal of Scientific Research in Science and Technology},
year = {2026},
volume = {13},
number = {4},
pages = {480--487},
doi = {10.32628/ijsrst2613466}
}
EUVIMED